Octreotide enhances rapamycin's antiproliferative action by inhibiting rapamycin-induced IRS-1 and Akt activation

被引：0
|
作者：
Cerovac, V [1 ]
Monteserin, J. L. [1 ]
Stalla, G. K. [1 ]
Theodoropoulou, M. [1 ]
机构：
[1] Max Planck Inst Psychiat, Neuroendocrinol Grp, D-80804 Munich, Germany
来源：
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES | 2009年 / 117卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：657 / 657
页数：1
相关论文
共 50 条
  • [1] The Prolyl Peptidases PRCP/PREP Regulate IRS-1 Stability Critical for Rapamycin-induced Feedback Activation of PI3K and AKT
    Duan, Lei
    Ying, Guoguang
    Danzer, Brian
    Perez, Ricardo E.
    Shariat-Madar, Zia
    Levenson, Victor V.
    Maki, Carl G.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (31) : 21694 - 21705
  • [2] BI 836845, a fully human IGF ligand neutralizing antibody, to improve the efficacy of rapamycin by blocking rapamycin-induced AKT activation
    Adam, Paul J.
    Friedbichler, Katrin
    Hofmann, Marco H.
    Bogenrieder, Thomas
    Borges, Eric
    Adolf, Guenther R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Desensitization of insulin action through Ser Thr phosphorylation and degradation of IRS-1 by activation of rapamycin-sensitive pathway
    Uno, T
    Haruta, T
    Usui, I
    Takano, A
    Kawahara, J
    Olefsky, JM
    Kobayashi, M
    DIABETES, 1999, 48 : A327 - A327
  • [4] Inhibition of Rapamycin-Induced AKT Activation Elicits Differential Antitumor Response in Head and Neck Cancers
    Radhakrishnan, Padhma
    Baraneedharan, Ulaganathan
    Veluchamy, Subhadra
    Dhandapani, Muthu
    Pinto, Dency D.
    Thiyagarajan, Saravanan
    Thayakumar, Allen
    Prasath, Arun
    Kamal, A.
    Velu, Ayyappan
    Jain, Misti
    Brijwani, Nilesh
    Narayanan, Prasad
    Kekatpure, Vikram D.
    Majumder, Biswanath
    Majumder, Pradip K.
    CANCER RESEARCH, 2013, 73 (03) : 1118 - 1127
  • [5] OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma
    Peng, Ke-Zheng
    Ke, Yu
    Zhao, Qi
    Tian, Fei
    Liu, Hong-Min
    Hou, Guiqin
    Lu, Zhaoming
    BIOCHEMICAL PHARMACOLOGY, 2017, 140 : 16 - 27
  • [6] PMA induced Ser/Thr phosphorylation of IRS-1 mediated by rapamycin-sensitive pathway
    Uno, T
    Kawahara, J
    Takano, A
    Iwata, M
    Usui, I
    Haruta, T
    DIABETES, 2000, 49 : A247 - A247
  • [7] Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling
    He, Xin
    Wang, Yu
    Zhu, Jinhong
    Orloff, Mohammed
    Eng, Charis
    CANCER LETTERS, 2011, 301 (02) : 168 - 176
  • [8] Combined SFK/mTOR Inhibition Prevents Rapamycin-Induced Feedback Activation of AKT and Elicits Efficient Tumor Regression
    Yori, Jennifer L.
    Lozada, Kristen L.
    Seachrist, Darcie D.
    Mosley, Jonathan D.
    Abdul-Karim, Fadi W.
    Booth, Christine N.
    Flask, Chris A.
    Keri, Ruth A.
    CANCER RESEARCH, 2014, 74 (17) : 4762 - 4771
  • [9] PDGF Receptor Alpha Is an Alternative Mediator of Rapamycin-Induced Akt Activation: Implications for Combination Targeted Therapy of Synovial Sarcoma
    Ho, Alan L.
    Vasudeva, Shyamprasad Deraje
    Lae, Marick
    Saito, Tsuyoshi
    Barbashina, Violetta
    Antonescu, Cristina R.
    Ladanyi, Marc
    Schwartz, Gary K.
    CANCER RESEARCH, 2012, 72 (17) : 4515 - 4525
  • [10] Inhibition of rapamycin-induced feedback activation of AKT with dasatinib induces complete tumor regression in a preclinical model of breast cancer.
    Yori, Jennifer L.
    Lozada, Kristen
    Seachrist, Darcie D.
    Mosley, Jonathan
    Abdul-Karim, Fadi W.
    Booth, Christine N.
    Flask, Chris A.
    Keri, Ruth A.
    CANCER RESEARCH, 2013, 73 (08)
12345